Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Amgen

EMA Backs Amgen Drug For Rare Autoimmune Disorder

The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended extending the therapeutic indication of Amgen Inc.’s (NASDAQ:AMGN) Uplizna (inebilizumab) to include the treatment of adult patients with active immunoglobulin G4-related disease (IgG4-RD).

Benzinga · Sep 19, 2025

Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis

Amgen Inc. (NASDAQ:AMGN) and Kyowa Kirin released preliminary topline results from the ASCEND study evaluating rocatinlimab in adults and adolescents with moderate to severe atopic dermatitis (AD) on Tuesday.

Benzinga · Sep 9, 2025

Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug

On Wednesday, Amgen Inc. (NASDAQ:AMGN) and its partner Zai Lab (NASDAQ:ZLAB) said the final analysis of the Phase 3 FORTITUDE-101 trial evaluating bemarituzumab in combination with chemotherapy (mFOLFOX6) in first-line gastric cancer has been completed.

Benzinga · Sep 4, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

Is Amgen Stock Underperforming the S&P 500?

Analysts continue to favor Amgen stock, despite its relative underperformance to the broader S&P 500 Index.

Barchart · Sep 1, 2025

BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up

BeOne Medicines Ltd. (NASDAQ:ONC) on Monday agreed to sell its royalty rights on the worldwide sales, excluding China, of Amgen Inc.’s (NASDAQ:AMGN) Imdelltra (tarlatamab-dlle) for up to $950 million to Royalty Pharma Inc. (NASDAQ:RPRX).

Benzinga · Aug 25, 2025

Amgen Stock Sinks As Market Eyes MariTide's Next Move

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday.

Benzinga · Aug 6, 2025

Amgen Delivers Beat And Raise Quarter; Has Strong Late-Stage Pipeline

Amgen Inc‘s (NASDAQ:AMGN) second quarter results demonstrate ongoing development of its late-stage pipeline “to offset end-of-decade losses-of-exclusivity," according to Goldman Sachs.

Benzinga · Aug 6, 2025

Read news from The Economist, FT, and more,
with one subscription

Stock Index Futures Gain on Strong Earnings and Fed Rate-Cut Bets

September S&P 500 E-Mini futures (ESU25) are up +0.24%, and September Nasdaq 100 E-Mini futures (NQU25) are up +0.30% this morning, extending a rebound driven by bets on Federal Reserve interest rate cuts and solid corporate earnings.

Barchart · Aug 5, 2025

Do Wall Street Analysts Like Amgen Stock?

Amgen has notably outpaced the broader market and the healthcare sector in 2025, and analysts remain cautiously optimistic about the stock’s prospects.

Barchart · Aug 4, 2025

AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate

AstraZeneca Plc (NASDAQ:AZN) on Thursday reported high-level results from the PREVAIL Phase 3 trial evaluating the safety and efficacy of gefurulimab in adults with generalized myasthenia gravis (gMG). The trial enrolled 260 patients.

Benzinga · Jul 24, 2025

Dow Leads as Merck, Amgen Gain: Stock Market Today

Second-quarter earnings season remained top of mind Tuesday, with Coca-Cola and GM among those reporting.

Kiplinger · Jul 22, 2025

Earnings Preview: What to Expect From Amgen’s Report

Amgen is set to release its second-quarter earnings next month, and analysts are projecting modest single-digit growth in profit.

Barchart · Jul 16, 2025

Honeywell, Caterpillar, Freeport-McMoRan And A Health Care Stock On CNBC's 'Final Trades'

As Wall Street looks ahead to the July 4 holiday weekend, a wave of optimism ripples through the trading floor, with seasoned investors poised to capitalize on emerging opportunities.

Benzinga · Jul 3, 2025

Career blocks for female scientists put under scrutiny

Talented female scientists are being pushed out of cancer research due to gender discrimination, ageism and an absence of mentorship, funding and job security.

AAP · Jun 26, 2025

Get all your
news in one place.

100's of premium titles.
One news app.

Windows Central · Jun 25, 2025

Microsoft Copilot is "pretty important" but customers still prefer ChatGPT — "OpenAI has done a tremendous job"

A new report suggests that Microsoft's sales division is struggling to differentiate Copilot from ChatGPT, with customers preferring OpenAI's offering.

The Independent UK · Jun 24, 2025

New once-a-month drug could treat diabetes and obesity, scientists say

Researchers say experimental drug’s less frequent dosing could improve adherence and offer long-term control

Benzinga · Jun 23, 2025

Amgen (AMGN) Stock Falls After Mixed MariTide Trial Update

Amgen Inc (NASDAQ:AMGN) shares are trading lower by 5.7% to $272.88 Monday afternoon after the company released full results from part one of its phase two study of MariTide, its investigational obesity treatment.

Barchart · Jun 9, 2025

How Is Amgen's Stock Performance Compared to Other Pharmaceuticals Stocks?

Amgen has underperformed the Pharmaceuticals industry over the past year, but analysts are moderately optimistic about the stock’s prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

Kiplinger · May 14, 2025

Stock Market Today: Nasdaq Outperforms as Big Tech Rallies

The Dow Jones Industrial Average closed lower for a second day as Amgen and Merck fell.

Barchart · May 5, 2025

Amgen Stock Outlook: Is Wall Street Bullish or Bearish?

Although Amgen has lagged behind the broader market over the past year, Wall Street analysts remain cautiously optimistic about the company’s long-term outlook.

MarketBeat · May 2, 2025

3 Biotech Giants Gaining From U.S. Sales and Policy Shifts

The significant domestic revenue base of select US biotech companies offers stability potential for investors navigating global trade complexities.

Barchart · May 1, 2025

Stocks Soar Before the Open on Upbeat Microsoft and Meta Results, More Big Tech Earnings on Tap

June S&P 500 E-Mini futures (ESM25) are up +1.18%, and June Nasdaq 100 E-Mini futures (NQM25) are up +1.68% this morning as forecast-beating quarterly results from Microsoft and Meta boosted sentiment.

Fortune · Apr 29, 2025

Elon Musk’s retreat from DOGE has lifted Tesla’s valuation by $158 billion—but the stock is still 50% off its peak

A TSLA stock rebound led to gains surpassing the current market caps of Amgen or Adobe.

Barchart · Apr 23, 2025

Analysts Think You Should Buy and Hold This 1 Dividend Stock ‘Forever’

Amgen stands out as a stable and attractive dividend stock, with a strong lineup of new medicines, a solid 3.45% forward yield, and a 201% dividend growth over the past decade.

Barchart · Apr 21, 2025

Amgen's Quarterly Earnings Preview: What You Need to Know

Amgen is scheduled to report its first-quarter results next month, and analysts expect a single-digit earnings growth.

1 2 3 4 5

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations